Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Prevalence SERO of Coronavirus Disease MESHD 2019 in Rheumatic MESHD Patients and Evaluation of The Effect of Disease-Modifying Anti-Rheumatic Drugs

    Authors: Soroush Moradi; Maryam Masoumi; Somayeh Mohammadi; Jamshid Vafaeimanesh; Mohaddeseh Mohseni; Hossein Mahdavi; Armin Aryannejad

    doi:10.21203/rs.3.rs-44445/v1 Date: 2020-07-16 Source: ResearchSquare

    Background: One of the most controversial issues among rheumatologists is the best approach to managing a rheumatic MESHD patient (RP) with coronavirus disease MESHD 2019 (COVID-19).Objectives: This study aims to evaluate the prevalence SERO of COVID-19 in RPs and compare it to thegeneral population (healthy individuals). Besides, it assesses the incidence of COVID-19 based on rheumatologic diseases MESHD ( RDs MESHD) categories and immunosuppressive (IS) drug history.Methods: In a cross-sectional study, all RPs of the rheumatology clinic of Shahid BeheshtiHospital, Qom, Iran were included (the case group), and the prevalence SERO of COVID-19 was compared to that in healthy individuals (the control group), between December 1,  2019, andFebruary 29, 2020. Qom city was the first city in Iran in which COVID-19 was identified and spread rapidly. The participants were recruited from hospital records for the case group and QomHealth Network’s database for the control group.Results: The prevalence SERO of COVID-19 is significantly less in RPs than in the healthy population.Moreover, patients who were under treatment with biologic diseas-modifying anti-rheumatic drugs(DMARDs) and IS drugs had milder symptoms in the case of COVID-19. Two RPs died from COVID-19, both of whom had granulomatosis HP granulomatosis MESHD and polyangiitis ( GPA MESHD).Conclusion: The prevalence SERO of COVID-19 in the RPs was lower than the general population, which was determined to be associated with more adherence to the quarantine and social distancing rules by RPs. Besides, using leflunomide (a DMARD) and IS drugs might have a protective effect against severe COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.